MNKD - Afrezza Total Debt to Capital

Public company logo of MannKind Corporation (MNKD)

MannKind Corporation (MNKD) minimizes geopolitical risks through local production in the US, although it remains dependent on Asian components. The total debt-to-equity ratio demonstrates current financial stability with the metric at 0.00. The company achieved a breakthrough by creating inhaled powder insulin. The business is now seeking to overcome product dependency by introducing treatments for rare lung pathologies.

MNKD: MannKind Total Debt to Capital 07/04/2022 - 11/01/2026
Core merchandise of Afrezza

The ratio is calculated as total liabilities divided by equity, making it sensitive to any changes in the liability structure. This metric determines the degree of financial leverage and the risk of the business's dependence on borrowed funds. For MannKind Corporation (MNKD), which utilizes outsourcing for production and logistics, this balance is critical for maintaining operational flexibility. Analyzing the company's debt leverage history allows for the timely identification of a dangerous increase in indebtedness. This trend warns investors against investing in a potentially insolvent asset.

Competitor analysis for MannKind Corporation

Debt to Equity Haleon|Kenvue Inc - Aggregate Debt to Equity|Total Debt to Capital VRNA|MENS (Jyong Bio) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital LGND (Ligand Pharmaceuticals)|Total Debt to Capital amneal.com AMRX|PRGO - Debt to Equity|All Debt to Shareholders' Equity Ratio ALVO (Alvotech S.A.)|Liquidia Technologies (LQDA) - Debt to Equity|Total Debt to Equity Ratio Galapagos Corp|ANIP (ANI Pharmaceuticals) - Total Debt to Capital|Total Debt to Capital amphastar.com|Total Debt to Equity Ratio PCRX (Pacira BioSciences, Inc.)|SPRY (ARS Pharmaceuticals Inc) - All Debt to Shareholders' Equity Ratio|Debt to Equity Theravance TBPH|Aquestive Corp (AQST) - Debt to Capital|SCPH: Total Debt to Equity Ratio|Tectonic Therapeutic, Inc. - Aggregate Debt to Capital|TNXP: Total Debt to Capital|China SXT Pharmaceuticals, Inc. - All Debt to Shareholders' Equity Ratio|EPRX (Eupraxia Pharmaceuticals, Inc.) - Total Debt to Capital|Debt to Capital BioHarvest Sciences Inc BHST|Debt to Equity eXoZymes Inc (EXOZ)|ORMP (oramed.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Entera Bio ENTX|HYFT - Total Debt to Equity Ratio|ABVC BioPharma Inc - Total Debt to Capital|CPIX - Total Debt to Capital|Quantum BioPharma Ltd (QNTM) - Debt to Equity|Debt to Equity Ratio FGEN|Debt to Equity Telomir Pharmaceuticals, Inc.|Debt to Equity Ratio RANI (Rani Therapeutics Inc)|Debt to Equity Synergy CHC Corp (SNYR)|Total Debt to Capital rallybio.com (RLYB)|Total Debt to Capital LEXX (Lexaria Bioscience Corp.)|Total Debt to Capital Coefficient pulmatrix.com (PULM)|PTHL - Debt to Equity|APM (Aptorum Group Limited) - Debt to Equity Ratio|LYRA: Total Debt to Capital|Debt to Equity Ratio IBO|Total Debt to Equity Ratio TNFA|YCBD: All Debt to Shareholders' Equity Ratio|Total Debt to Capital PRFX|Total Debt to Equity Ratio altamiratherapeutics.com CYTO|Debt to Equity Lipella LIPO|OptiNose Corp (OPTN) - Debt to Capital|PIRS - Debt to Equity|All Debt to Shareholders' Equity Ratio PROC (procapsgroup.com)|Petros Pharmaceuticals, Inc. (PTPI) - Debt to Equity|Aggregate Debt to Equity QLI (Qilian International Holding Group)|Debt to Equity ACELYRIN, Inc.|Debt to Capital TFF Pharmaceuticals, Inc TFFP